10/24/2013 | PP | Ziopharm Oncology prices $50.05 million public stock offering at $3.50
|
10/22/2013 | PP | Ziopharm to conduct $50 million public offering of stock via JPMorgan
|
1/20/2012 | PP | Ziopharm Oncology prices $50.18 million public stock offering at $5.20
|
1/19/2012 | PP | Ziopharm Oncology intends to price public offering of common stock
|
11/7/2011 | CVHYPF | Ziopharm files $150 million shelf covering preferreds, debt and stock
|
4/30/2010 | CVHYPF | Ziopharm files $100 million shelf covering preferreds, debt, stock
|
9/15/2009 | PP | New Issue: Ziopharm Oncology concludes $5.06 million private placement of units
|
9/14/2009 | CVHY | Ziopharm files $75 million shelf for stock, debt, preferreds, warrants
|
9/9/2009 | PP | New Issue: Ziopharm Oncology negotiates $5.05 million private placement of units
|
9/9/2009 | PP | Market Commentary: Galway seeks exploration funding; Savoy Energy secures equity line; Prana to raise A$6 million
|
2/16/2007 | PP | Market Commentary: First BanCorp to close $94.8 million stock deal; large offerings may be result of acquisitions surge
|
2/16/2007 | PP | New Issue: Ziopharm Oncology arranges $30.88 million placement of units
|
9/20/2006 | BT | Ziopharm receives Nasdaq approval for capital market listing
|
9/14/2006 | BT | Ziopharm: study supports development of ZIO-101 as cancer treatment
|
9/13/2006 | BT | Ziopharm says it will announce details of third clinical program this year
|
6/5/2006 | BT | Ziopharm presents data showing ZIO-201 avoids adverse effects of ifosfamide
|
6/2/2006 | BT | Ziopharm: Interim results of ZIO-101 show clinical benefit for solid tumors, leukemia
|
5/3/2006 | BT | Market Commentary: MGI, SuperGen get nod from FDA for Dacogen; Impax stock climbs on FDA OK of generic Colestid
|
5/3/2006 | PP | Market Commentary: Axcelis raises $75 million from convertibles; HydroGen secures $25.78 million from stock sale
|
5/3/2006 | BTPP | New Issue: Ziopharm Oncology wraps $37 million stock sale
|
4/5/2006 | BT | Ziopharm data shows ZIO-101 kills myeloma cells
|
4/3/2006 | BT | Ziopharm says ZIO-201/202/203 shows anticancer activity in leukemia, pancreas, prostate cancers
|
3/22/2006 | BT | Ziopharm Oncology says net loss up 67% in 2005 due to greater R&D activity
|
2/23/2006 | BT | Ziopharm treats first patient in ZIO-201 phase 1/2 study in sarcoma
|
2/21/2006 | BT | Ziopharm data shows ZIO-201 less likely than other metabolites to cause kidney damage
|
2/17/2006 | BT | Ziopharm preclinical data suggests ZIO-201 may enhance blood cell, bone marrow transplants
|
1/31/2006 | BT | Ziopharm doses first patient in phase 1/2 study of ZIO-101 for myeloma
|
1/17/2006 | BT | Ziopharm receives notice of allowance on use of organic arsenic for treatment of cancer
|
1/4/2006 | BT | Ziopharm to begin phase 1/2 trial of organic arsenic as treatment for myeloma
|
11/21/2005 | BT | Ziopharm's ZIO-101 compound may be effective against arsenic trioxide-resistant cancer
|
11/18/2005 | BT | Ziopharm Oncology says research of ZIO-102 shows it may help to design more specific cancer treatment
|
9/26/2005 | BT | Ziopharm Oncology changes symbol to "ZIOP"
|